Latest / Decera Clinical Education Oncology Podcast
Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer
In this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Topics include:
Data from the PEACE-3 trial on the effect of bone-protective agents on fracture risk with enzalutamide plus radium-223
Efficacy and toxicity of PSMA lutetium plus standard of care in the VISION trial
Ongoing trials evaluating radionuclides in combination with other agents in metastatic CRPC
Presenters:
Chris Parker, MD
Professor of Prostate Oncology…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.